In the latest blow to the controversial multiple sclerosis drug Tysabri, the U.S. Food and Drug Administration announced that it was slapping a new warning on the drug’s label.
In an advisory sent to health-care professionals and patients, the FDA warned that the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but deadly brain infection, increases as more infusions are received.
Natalizumab (Tysabri) first received FDA approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed PML.
We have a remarkable medicine for multiple sclerosis patients called cannabis. We have research showing that it relieves the symptoms of MS and may even halt or slow its progression. It has absolutely zero deadly side effects, no matter how many infusions of cannabis one takes. Yet MS patients in 36 states cannot access this medicine without facing arrest and incarceration. MS patients in 14 other states are repeatedly taunted by the opponents of medical marijuana that “anecdotes are not evidence” and “it’s not been approved by the FDA.”
http://stash.norml.org/fda-approved-ms-drug-requires-new-label-due-to-deadly-side-effect